Print Page   |   Contact Us   |   Your Cart   |   Sign In
Sign In

Forgot your password?

Haven't registered yet?

Breaking News
News & Press: Daily Updates

MMWR: Notes from the Field: Administration Error Involving a Meningococcal Conjugate Vaccine — Unite

Thursday, February 18, 2016   (0 Comments)

Menveo (GlaxoSmithKline, previously Novartis AG) is a conjugate vaccine that was recommended in October 2010 for routine use in adolescents (preferably aged 11 or 12 years, with a booster at 16 years), and among persons aged 2 through 54 years with certain immunosuppressive conditions, to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (1). 


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2016. Sponsorship does not imply endorsement by OSAP of a company's products or services.